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C H A P T E R  5
5 summary
Nutrit ion plays an important role in the pathophysiology of (chronic) disease (chapter "l ).
The rapidly dietary changes in the past century may at least in part be at the basis of the
high r isk of  some typical ly  Western d iseases,  inc luding coronary hear t  d isease (CHD),
diabetes mellitus, certain cancers, chronic obstructive pulmonary disease, dementia and
osteoporosis. Among the most important dietary changes are excessive macronutrient
intakes (giving rise to overweight), insufficient micronutrient intakes (giving rise to
subcl in ica l  def ic iencies)  and nutr i t ional  imbalances.  In  th is  thesis ,  we have focused on the
diagnosis of subclinical micronutrient deficiencies and the augmentation of micronutrient
status.
Many investigations have concentrated on the effects of single nutrients on risk of disease.
The evidence is particularly strong for the relation between low co3 fatty acid (FAcD3) status,
padicularly long chain polyunsaturated FAro3 (LCPo3) status, and increased CHD risk.
The evidence for a relation between low folate status and elevated CHD risk is expanding,
although final proof of a causal relation awaits the outcome of randomized controlled trials
with CHD endpoints. The folate-CHD relation is probably caused by an increased plasma
total homocysteine concentration (tHcy) (chapter '1 .3).
The recognition of the relations between micronutrients and disease has changed
both the perspectives of the nutrit ional guidelines for whole foods and the Dietary
Reference Intakes [DRls; either recommended dietary allowances (RDA) or adequate
intakes (Al)l for nutrients, from prevention of clinical nutrient deficiency towards disease
prevention. For some vitamins, it is nowadays recognized that the higher DRI levels cannot
always be met with intakes of the recommended iet. The finding from the most recent
Dutch National Food Consumption Survey that many subjects in The Netherlands do not
meet nutritronal recommendations suggests that improvement oÍ the diet may decrease the
risk of (chronic) disease in the Dutch population (chapter 1.4). Dietary assessments are
less suitable for establishment of micronutrient deÍiciencies in individuals than laboratory
tests. Reference values of so-called 'static parameters' of micronutrient status are
commonly employed to establish micronutrient deficiency, but these cannot be used Íor the
evaluation of subclinical deficiencies. Cut-off values of subclinical deficiencies are
preferentially based on the relation between micronutrient status and disease risk, but
these relations are diff icult to study. Consequently, only few of these are currently known in
detail. The cut-off values may alternatively be based on the relation between so-called
'functional parameters' and either static parameters or micronutrient intakes. The choice oÍ
the parameter and its cut-off value depends the action following the test outcome, while
taking benefits, hazards and costs into account (chapter 1.5). The micronutrient status may
be optimized either by dietary advice, nutrient supplement intakes orfood Íortif ication. The
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-riï possibilities are commonly accepted Íor the prevention of (chronic) disease and
clinical nutrient deficiency, respectively. Intervention may also be indicated when the mean
nutrient intakes in populations do not meet the DRl, i.e. when (sub)populations have high
risk of nutrient deficiency. This is particularly applicable when the specific nutrient is
causally related with an increased risk of developing (chronic) disease or with severe
clinical nutrient deÍiciency symptoms (chapter 1.6).
Chapter 2 is Íocused on homocysteine (Hcy). Increased plasma tHcy is associated with
increased risk of coronary, cerebral and peripheral vascular disease.
Hyperhomocysteinemia (HHcy) may e.g. be caused by low folate, vitamin Brz and vitamin
Bo status, and by impaired renal function. Folate status is the main determinant of plasma
tHcy in Western populations. Although there is as yet no definit ive proof that the relation
between high plasma tHcy and cardiovascular disease (CVD) is causal, it nevertheless
seems that lowest plasma tHcy confers lowest disease risk.
In chapter 2.1, we used plasma tHcy to investigate the folate, vitamin Brz and vitamin Bo
status in subjects from íour different populations. In two of these, we focused on treatment
of  HHcy (2.1.3 and 2.1.4) .
In chapter 2.1.1, we investigated whether formula-fed infants had different plasma
tHcy compared with breast-fed counterparts, and during what time period any difference
developed. For this, we determined plasma tHcy in 53 formula-fed and 15 breast-fed
healthy low-birth-weight babies (<2500 g) around days 10,20 and 40. We found that
breast- and formula-Íed infants have similar plasma tHcy until 20 postnatal days and that
plasma tHcy subsequently increases from day 20 to day 40 in breast-fed infants, but not in
formula-fed counterparts. Plasma tHcy was inversely related with formula (day 10) and
human milk (day 40) volume intakes. Hcy concentrations in human milk were found to be
low. The gradually increasing plasma tHcy in breast-Íed, but not in formula-fed, infants may
be caused by lower folate, vitamin 812, vitamin Bo and vitamin 82 concentrations in human
milk. Low milk B-vitamins may derive from gradually developing suboptimal B vitamin
status in the mother with duration of lactation. lt remains to be established which of the four
vitamins is primarily responsible for the encountered plasma tHcy difference between
formula- and breast-fed infants.
Indian subjects, in particular subjects of Indian descent who migrated to other
countries, have as yet poorly understood high CVD risk. Their risk is not accounted for by
risk factors such as cigarette smoking, hypercholesterolemia or hypertension, but may be
explained by high prevalence of diabetes mellitus and the combination of high triglycerides
and low HDl-cholesterol, as combined in the syndrome X. A combination of low vitamin
Brz and high plasma tHcy, caused by the Indian vegetarian diet, may also be a factor in
their increased CVD risk. In chapter 2.1 .2, we determined plasma tHcy and circulating
vitamin Bo, vitamin Brz and folate concentrations in 41 Indian subjects and compared their
values with those of 51 black and 26 Caucasian adults. All subjects l ived in the island of
Curagao (Netherlands Antil les). Plasma tHcy and circulating vitamins were also monitored
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folic acid in pharmacological dosages. Compared with the other two groups, the Indians
had h ighest  prevalence of  low v i tamin Brz status (63%) and HHcy (51%).  Their  p lasma
tHcy did not change upon supplementation with vitamin Bo, but decreased upon vitamin Brz
and to a lesser extent upon folic acid. We concluded that low folate and notably low vitamin
Brz status cause high HHcy prevalence in the investigated Indian population, and suggest
that HHcy may be a factor in their high CVD risk.
In chapter 2.1.3, we determined the optimal vitamin dose for pediatric patients with
sickle cell disease (SCD), as derived from the abil ity of these vitamins to lower plasma
tHcy. SCD is a single gene inheritable disorder that is pathophysiologically characterized
by endothelial dysfunction with chronic and occasionally exacerbating components. From
the grossly decreased erythrocyte (RBC) half-l ives of SCD patients, it might be expected
that they have higher folate needs. We previously showed that these patients indeed have
subclinical folate deficiency, as derived from their high, and folic acid responsive, plasma
tHcy. Lowering plasma tHcy in SCD patients by B-vitamin supplementation may reduce
their inherently high risk of endothelial damage. Twenty-one pediatric SCD patients (1'1
HbSS, 10 HbSC; 7-16 years)  par t ic ipated in  th is  82 weeks dose-escalat ion study.  Dai ly
folic acid, vitamin Brz and vitamin 86 supplements were gradually increased and blood was
taken at 9 occasions for measurements of plasma tHcy and circulating vitamin
concentrations. Lowest plasma tHcy was reached from 700 pg (3.5-7 US 1989 RDA) folic
ac id,  3 US 1989 RDA (4.2-6.0 pg)v i tamin Brz and 3 US 1989 RDA (4.2-6.0 mg)v i tamin 86.
In practice, this translates in daily dosages of 1 mg folic acid, 6 pg vitamin Brz and 6 mg
vitamin 86. We propose to prescribe this vitamin regimen to all pediatric SCD patients,
since it may reduce their high risk of endothelial damage by simple and relatively
inexpensive means.
Lack of proof of a causal relation between plasma tHcy and CVD precludes institution
of a public health policy to improve Íolate status of the general population. In chapter 2.1.4,
we investigated the effect of intensive nutrit ional education regarding a Mediterranean type
of diet on plasma tHcy. The study was performed in the context of a controlled community-
based CVD prevention project with 30-70 years old subjects. Their serum total cholesterol
was 6-8 mmol/l and they had at least two other CVD risk factors. The intervention group
(n=97) received intensive dietary education at weeks 4,6, 12 and 40, whereas the control
group (n=153) received a posted leaflet with the standard Dutch nutrit ional guidelines at
baseline. One of the targets was to reach a 200 gld fruit and vegetable intake difference
between the intervention and the control groups. Plasma tHcy was measured at baseline
and after'1 6 and 52 weeks. When compared with the control group and adjusted for
baseline intake and gender, the intervention group increased after 16 and 52 weeks their
combined fruit and vegetable intake with 77 and 62 gld, respectively. Their plasma tHcy did
not change. Also other studies have shown that nutrit ional education is moderately
effective in changing fruit and vegetable intakes on a population level. We therefore
conclude that nutrit ional education regarding a Mediterranean type of diet does not reduce
plasma tHcy to an appreciable xtent, and that this may also apply to other dietary advises.
Folic acid fortif ied foods are l ikely to be more effective for plasma tHcy lowering on a
populat ion level .
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In chapter 2.2, we described our four studies on the laboratory diagnosis of HHcy. There is
as yet no consensus for HHcy diagnosis and treatment, mainly because the evidence for a
causal relation is as yet lacking.
The upper l imit of the plasma tHcy reference values, i.e. 15 pmol/l as derived from
apparently healthy subjects, is generally used as cut-off value for HHcy establishment. The
reÍerence population may however include subjects with subclinical folate, vitamin 812 and
vitamin Bo deficiency. Since these deficiencies are associated with increased CVD risk, this
15 pmol/l cut-off value is l ikely to be too high for HHcy establishment in CVD risk
assessments. Future demonstration of a beneficial effect of plasma tHcy lowering on CVD
risk would justify the use of plasma tHcy reÍerence values as established at optimized
vitamin status. In chaoter 2.2.1, we determined vitamin-optimized plasma tHcy reference
values and investigated their influence on the prevalence of HHcy in healthy adults.
Results were compared with HHcy prevalences as obtained by using 'European Concerted
Action Pro.lect' (ECAP) cut-off values. Apparently healthy adults (n=101) received
pharmacological dosages of folic acid, vitamin Brz and vitamin 86 during a four weeks
study period. We determined both íasting (ttHcy) and 6h post methionine load (postload-
tHcy) plasma tHcy at baseline and after 4 weeks. Baseline (4 weeks) f-tHcy and postload-
tHcy reference values were 4.7-14.6 (4.1-9.3)  and 18.8-49.7 (12.9-35.1)  pmol / | ,
respectively. Mean ftHcy and postloadtHcy decreased after 4 weeks vitamin
supplementation by 3.5 (33.5%) and 8.5 (26.3%) pmol/|, respectively. The percentage
subjects exhibit ing significant decreases of f-tHcy following vitamin supplementation
amounted to 88% (all subjects), 92% (non-vitamin users) and 72oÁ (vitamin-users). HHcy
prevalences with use of ECAP cutoff values were: 29oÀ (all), 29o/" (men), 27% (pre-
menopausal women) and 53% (post-menopausal women). With vitamin-optimized cut-off
values they were: 58, 58, 76 and 89%, respectively. We concluded that the use of vitamin-
optimized cut-off values gives rise to high HHcy pre{est probabil it ies in the general
population and therefore precludes any meaningful role for plasma tHcy testing.
The results presented in chapter 2.2.1 not only showed that use of vitamin-optimized
cut-off values increased the diagnostic value of f{Hcy, but also that it decreased the value
of a postload{Hcy, when compared with use of ECAP cut-off values. These findings were
studied into more detail in chapter 2.2.2. In a retrospective study design we determined the
diagnostic value of f-tHcy and the added value of postload{Hcy with use of several plasma
tHcy cut-off values for HHcy assessment in 177 healthy subjects and in 3,477 subjects with
plasma tHcy test indications. Cufoff values were based on reference limits (f{Hcy <15.0;
postloadtHcy <50.0 pmol/l), relative risk (f-tHcy <12.0, postload-tHcy <38.0; or f{Hcy
<10.0 pmol/l) and vitamin-optimized reference limits (f{Hcy <9.3; postload{Hcy <35.1
pmol/l). Use of the American Head Association (AHA) 10 pmol/l f{Hcy cut-off value gave
HHcy prevalences oÍ 65% in subjects with plasma tHcy test indications and 50% in healthy
subjects. The combination of the vitamin-optimized reference limits for Í-tHcy and postload-
tHcy gave a HHcy prevalence of 79% in subjects with plasma tHcy test indications, of
which only 5% was on account of increased postloadtHcy. Corresponding values for
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employment of a 10 pmol/l (AHA) or 9.3 pmol/l (vitamin-optimized reference values) cut-off
value, and the low added value of a postload-tHcy, supported our previous conclusion that
there is no indication for plasma tHcy testing from an evidence-based point-of-view.
To determine whether fasting conditions are necessary for HHcy diagnosis, we
studied intra- (CV) and inter- (CVn) individual biological variation of plasma tHcy and
factors that influence biological variation (chapter 2.2.3). Three-week biological variation
was calculated from 9 samples of 6 adults, taken at Mondays, Wednesdays and Fridays at
three different clocktimes. Within-day plasma tHcy changes and variation were studied in
16 heal thy adul ts  at  8:00,  10:00,  12:00,  1400,  16:00,  18:30 h,  and in 10 of  them af ter  3
weeks supplementation with pharmacological dosages of folic acid, vitamin Brz and vitamin
Bo.  A standardized breakfast  (8:15 h)  and lunch (12:15h) was provided ur ing these days.
Between-day CV and CVn were 9.9 and 25.6%, respectively. Between-day CV1 and CVs
were insignificantly highest at 8:00 h and lowest at '14:00 h. Within-day plasma tHcy
decreased from 8:00h-10:00 h and was associated with orotein intake in the orevious
evening. From the similarity between our biological variation coefficients and the
standardized biological variations published by other investigators, and from the similarit ies
of our time-speciÍic CV and CVn, we concluded that fasting is not necessary for plasma
tHcy analysis. The relation between within-day plasma tHcy changes and protein intakes
prior to testing, and insignificantly lowest CVi and CVn after 16 h of low protein intake,
indicates that protein intake standardization prior to testing might lower biological variation,
but its extent is as yet unknown.
ln chaoter 2.2.4, we discuss the recommendations of The Netherlands Heart
Foundation (NHS) for the diagnosis, screening and treatment of HHcy. With these
recommendations, the NHS encourages the development of a consensus for HHcy
diagnosis and treatment and provided us with an appreciated init iative that brings the Hcy-
CVD risk relation to the attention of the medical profession. Their recommendation may, in
our opinion, be sharpened and simplif ied. To increase uniformity, we suggest to use a
single cufoff value for HHcy diagnosis and HHcy treatment goal. The, in our opinion,
preferable ftHcy cut-off value amounts to 10 pmol/|, since this value is a consensus based
on the relation between plasma tHcy and CVD risk from several studies. Moreover, it is
concordant with the P97.5 of healthy subjects after vitamin-optimization. An additional
advantage is that use of this cut-off value renders vidually no added value for the
methionine load test (MLT). Treatment with a folic acid, vitamin Brz and vitamin Bo
combination, as opposed to the recommended stepwise treatment regimen, reduces the
number of clinical chemical tests, reduces the risk of masking vitamin B12 deficiency, and
possibly increases therapy compliance.
Chapter 3 is focused on essential fatty acids (EFA). EFA include FA oÍ the rrÉ and co6
series. lt is assumed that we have evolved on a co6/co3 ratio of 111 Io 511. FAoS intakes
have however increased in the past 100 years at the expense of FAor3 to a current o16/o13
ratio of over 15/1 . The relation between increased FAor3 intakes and reduced CVD risk
suggests that the increased FArr>6 consumption has eventually caused a state of
subclinical FAco3 deficiency. The LCPo3, eicosapentaenoic (EPA) and docosahexaenoic
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(DHA) acids, are mainly held responsible for the beneficial effects of FAor3. These FA
derive mainly from the diet, notably fish, but may also be synthesized endogenously from
the parent EFA u-linolenic acid (ALA). Synthesis of LCPro3, particularly of DHA, is however
l imi ted.
The a im of  the studies in  chapter  3.1 (3.1.1-3.1.6)  was to invest igate whether  LCPro3,
notably DHA, are (condi t ional ly)  essent ia l .
In  chapter  3.1.1,  we compared the polyunsaturated Íat ty  ac id (PUFA) status of  Dutch
vegans and omnivores to investigate whether different diets and LCP synthesis rates might
explain disparit ies. For this, we investigated ietary intakes and fatty acid compositions of
RBC, platelets (PLT), plasma cholesterol esters (CE) and plasma triglycerides (TG) of 12
vegans and 15 age- and sex-matched omnivores. In general, vegans had lower o3 status
and h igher  o16 status,  inc luding y- l ino lenic  ac id (GLA) and d ihomo-y- l ino lenic  ac id (DGLA)
but not arachidonic acid (AA). Vegans had lower AA (TG) after normalization of PUFA to
100o/o. Normalization of eicosanoid precursors to 100% revealed similar AA (all
compartments) ,  h igher  DGLA (TG) and lower EPA (a l l ) .  High o$,  notably l ino le ic  ac id (LA),
and low ro3, notably EPA and DHA, status in Dutch vegans derive from low dietary LCPro3
and ALA/LA ratio. Higher GLA and DGLA in their TG may reflect higher hepatic AA
production rate, whereas higher AA and 22:4ofi in omnivores indicates AA intake from
meat.
In the subsequent wo chapters, we investigated in two short{erm supplementation
studies whether  GLA or  car t in ine a lone,  or  in  combinat ion wi th ALA, augment  ALA
conversion to LCPo3. lt has been speculated that these Íactors enhance LCPcÉ synthesis
from ALA by increasing À6-desaturase activity (GLA), or by stimulating FA transport across
the peroxisomal membrane (carnitine). ïhe latter would be necessary for LCP synthesis
according to the pathway proposed by Infante et al. The studies were performed with
subjects consuming vegan or lacto-ovo-vegetarian diets, since these subjects may have
litt le negative feedback inhibit ion from dietary LCP on the conversion of ALA to EPA and
DHA. Moreover, they might be expected to have low carnitine status, because of their low
consumotion of carnitine-rich foods such as meat.
The GLA study (chapter  3.1.2)  was per formed wi th 9 apparent ly  heal thy vegans,  who
were requested to consume ei ther  2.0 g ld ALA (4 ml  l inseed o i l )  or  1.2 g/d GLA (6 ml
borage oil) during the first four weeks and their combination in the subsequent four weeks.
The LCPcÉ contents before and after each supplementation period were determined in
RBC, PLT,  CE, TG and p lasma phosphol ip ids (PL) .  The supplements changed the d ietary
LA/ALA rat io  ( in  g/g) f rom about  13.7 (basel ine) to 6.8 ( l inseed o i l ) ,  14.3 (borage o i l )  and
6.4 ( l inseed+borage o i l ) ,  respect ive ly .  ALA or  GLA given as s ingle supplements d id not
increase LCPor3 status, but their combination augmented LCPco3 (in CE) and EPA (in
fasting TG) to a statistically significant, but nevertheless negligible, extent. Our results were
similar to those of our previous study with omnivores. We therefore concluded that neither
GLA, nor negative feedback inhibit ion by dietary LCP, is an important factor in the inabil ity
to augment notably DHA status by dietary ALA. The reach of a DHA plateau already at low
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alternatively, that dietary DHA is important for maintaining DHA status at a functionally
re levant  level  ( i .e .  that  DHA intake is  essent ia l ) .
Twenty apparently healthy vegans and lacto-ovo-vegetarians participated in the
carnitine study (chapter 3.1.3). They were requested to consume 990 mg/d l-carnitine or
2.0 gld ALA (4 ml/d l inseed oil) during the first four weeks and their combination in the
subsequent Íour weeks. FA compositions of RBC, PLT, CE and TG were measured at
baseline and after 4 and I weeks. Carnitine supplementation i creased plasma free and
total carnitine concentrations, but did not affect EPA and DHA contents of any of the
investigated compartments. EPA and DHA changes were however inversely related to
init ial carnitine status. Our results did not suggest that carnitine is an important l imiting
factor, if any, for LCPo3 synthesis. The most efficient means to augment EPA and
particularly DHA status remains consumption of LCPot3 from e.g. f ish or supplements.
In chapter 3.1.4, we investigated the effect of high dose EPA supplementation on
DHA synthesis. For this, we investigated the plasma, RBC and PLT FA profi les of a patient
with mantle cell lymphoma, who had taken 12 gld of ethyl-EPA for 16 months. Long-term
ethyl-EPA consumption did not cause adverse side effects. EPA and its elongation product
22:5ot3 were highly elevated in all compartments, but DHA was within reference range. AA
was moderately reduced, but DGLA remained within l imits. In spite of an LCPor3 intake
higher than in most Inuit populations, AA levels remained considerably higher in this
patient when compared with Inuits. The absence of effects on DGLA and DHA, and the
modest effect on AA in PLT, indicate that levels of these key FA may be subject to strong
homeostatic regulation.
The homeostatic regulation of DHA status may be different in men when compared
with women, since it was recently shown that women of child-bearing age have higher
capacity for ALA conversion to LCPco3 than men. This observation was suggested to
reflect the high DHA demands of fetuses and neonates during pregnancy and lactation,
respectively. In chapter 3.1.5, we investigated in a retrospective design whether gender
difference in RBC EFA status were demonstrable. For this we reviewed the RBC FA
compositions that were used for the assessment oÍ reference values for EFA and FAo3
status (see chapter 3.2). The apparently healthy study groups comprised 59 babies (2-46
days o ld) ,33 in fants (3.5 years)  and 61 adul ts  (22-49 years) .  Babies and infants d id not
show differences in RBC FA that were based on gender. On the other hand, male adults
had higher RBC 22:5ro3, and insignificantly lower DHA, when compared with Íemale adults.
The DHA difference became significant after inclusion of data from 8 vegan adults. No
differences were observed in RBC FAtrS, apart from higher RBC 22:5co6 in women, when
compared with men. The encountered lower 22:5at3 in combination with higher DHA in
women is in agreement with their higher ALA to DHA conversion capacity as noted by
others. ln addition, our data suggest higher conversion rate to 22:5atà and thereby adds to
the notion that women of childbearing age exhibit increased A4-desaturation activity.
In the l iterature study presented in chapter 3.1.6, we investigated whether LCPol3,
and notably DHA, are essential. Dietary intervention trials, including those presented in the
previous chapters, and stable isotope studies revealed that humans are poor DHA
synthesizers. There is circumstantial evidence that we evolved on a diet with higher LCP
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content and 0É/06 ratio, and that the AA and DHA needs to expand our brain were mainly
covered by the diet. Early African hominid species l ived at the margins of lakes and rivers
and at the seashore, eating diets abundant of EPA and DHA, but also AA, from easily
caught fish and other animals l iving in the water vicinity. The presently low intake of ALA
and LCPcrÉ from the Western diet is associated with CVD, inflammatory disorders, and
mental  and psychiat r ic  d iseases,  and to subopt imal  neurodevelopment  i  neonates.  The
strongest indications for a current subclinical crÉ deficiency come from randomized
controlled trials with LCPor3, showing reduced mortality from CVD and improved neonaial
neurodevelopment .  Wi th notably these studies in  mind,  we conclude that  DHA is  essent ia l .
Early suspicion of EFA deficiency (EFAD) or rrÉ-deficiency may rather focus on FA
analyses than clinical symptoms. Reference values of static markers of EFA status are oÍ
l imited value for the detection of these conditions, since many subjects in the reference
population have inherently high CVD risk. Within-reíerence range EFA status may
consequently not be synonymous with low risk of (chronic) disease. There are
unfortunately as yet no functional markers for EFA status that are related to increased
disease risk. In chapter 3.2 we investigated new functional markers, i.e. RBC 20:3rog
(Mead acid), 22:5o$120:4ofi and 22:5afi122:6trr3, that can be used for the early detection
of biochemical EFAD, oÉ- and to3/DHA-deficiencies, respectively. Their cutoff values were
based on 97.5 percentiles of RBC FA data that derived from apparently healthy groups oÍ
omnivorous ubjects (n=205) and subjects with low dietary LCP intakes (n=93; i.e. vegans
and formula-fed infants). Cut-off values were evaluated by their application in an EFAD
suspected group of  108,  most ly  malnour ished,  Pakistani  ch i ldren,  three pediat r ic  pat ients
with chronic fat-malabsorption and one patient with a peroxisomal B-oxidation disorder.
The proposed cut-off values are applicable Íor ages above 0.2 years, since all parameters
proved age-dependent  up to that  age.  The omnivorous and low dietary LCP groups had
similar RBC 20:3o9 and RBC 22'.5ot6120:4ot6, indicating that these parameters are
independent of dietary LCP intakes. Cut-off values for EFAD and oÉ-deficiency were 0.46
mol% RBC 20:3ro9 and 0.068 mol/mol RBC 22:5o6120:4tl6, respectively. Since the
omnivorous and low dietary LCP groups had different RBC 22:5ttf i122:6ut3, we advised two
cut-off values for o3/DHA status. i.e.0,22 mol/mol RBC 22:5aÉ122.6oo3 for o3/DHA-
marginality and 0.48 mol/mol RBC 22:5oÉ122:6al3 for co3/DHA-deficiency. Use of RBC
20:3c09 and 22:5ot6120:4o6 cut-off values classified 20.4% of the Pakistani children as
EFAD+crÉ-deÍicienI, 12.9% as EFAD+oÉ-sufficient, 38.9% as EFA-sufficient+ro3-deficient
and 27.8o/o as EFA-sufficient+co3-sufficient. The patient with the peroxisomal disorder was
classified as EFA-sufficient, o3-sufficient (based on RBC 22:5ofi120:4ruc6) and co3/DHA-
deficient (based on RBC 22:5a1l22:6ct3). The three other pediatric patients were classified
as EFAD, ro3-deficient and co3/DHA-deÍicient. We propose to use present cut-off values for
EFA, o3 and oÉ/DHA status assessment for the decision to init iate PUFA
supplementation, unti l better concepts have emerged.
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